专家识别在Covid-19反应中扩展和改善抗体测试的步骤

来自联邦政府，工业和学术界的300多名科学家和临床医生发表了关于Covid-19血清学研究的结论和建议的报告免疫力。该小组于5月举行了一次在线研讨会，讨论血清学检测在理解和应对COVID-19公共卫生危机方面的作用，并探讨应对这一新兴领域关键科学知识机会和差距的战略。COVID-19血清学检测旨在检测导致COVID-19的病毒SARS-CoV-2的抗体。虽然这种检测不能诊断活动性感染，但它们可以表明以前感染过SARS-CoV-2，而这种感染可能被遗漏了，因为一个人在感染时没有出现显著症状或未接受检测。

The COVID-19 Serology Studies workshop was convened by an interagency working group comprised of experts from the U.S. Department of Health and Human Services—including scientists at the National Institute of Allergy and Infectious Diseases (NIAID), the National Cancer Institute (NCI), and the National Heart, Lung and Blood Institute (NHLBI), parts of the National Institutes of Health, as well as the Centers for Disease Control and Prevention and the Biomedical Advanced Research and Development Authority—and the Department of Defense. Attendees assessed efforts to better understand the implications of serology test results, to produce and validate test kits, and to quantify undetected cases of SARS-CoV-2 infection.

与会者建议，需要进一步研究，以确定抗体测试呈阳性是否以及在多大程度上意味着一个人可以免于再次感染SARS-CoV-2。与会者强调，在获得此类数据之前，不应将血清学检测用作与SARS-CoV-2暴露相关的个人安全决策的独立工具。研究人员目前正在对人类和动物模型进行研究，以更好地了解SARS-CoV-2免疫。与会者指出，这种理解有助于确定恢复期血浆的最佳献血者，这些血浆可能被用于帮助治疗严重COVID-19患者。

---

---